METTL3 and neoplasm: For all 197 patients, in addition to clinical stage (HR: 3.827, P = 0.003), N status (HR: 3.219, P = 0.021) was an independent factor for DFS, clinical stage (HR: 4.248, P < 0.001) was an independent factor for OS, and METTL3 levels in tumour cells (HR: 3.157, P = 0.022) and in tumour-infiltrating immune cells (HR: 3.368, P = 0.036) and CD33+ MDSCs (HR: 3.958, P = 0.031) were independent factors for both DFS and OS (Table 4).